Global Cutaneous Squamous Cell Carcinoma Market - 2022-2029

Market Overview

Cutaneous Squamous Cell Carcinoma Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 7.2 % during the forecast period (2022-2029).

Cancer starts in the cells that make up the epidermis (the outer layer of the skin). It commonly develops in parts of the skin that have been exposed to long periods of natural or artificial sunlight (such as from tanning beds). The face, ears, lower lip, neck, arms, and backs of the hands are examples of these locations. It can also happen if you've had your skin burned or exposed to chemicals or radiation. A hard red bump, a scaly red patch, an open sore, or a wart that crusts or bleeds easily can all be signs of cutaneous squamous cell carcinoma. Squamous cell carcinoma of the skin that hasn't spread can typically be cured.

Market Dynamics

Increasing noninvasive diagnostic techniques for Cutaneous Squamous Cell Carcinoma is expected to drive market growth.

Diagnosis of advanced cSCC involves experts from different specialties, including dermatologists, anatomical pathologists, surgeons, radiation oncologists, and medical oncologists, thereby enabling a more comprehensive patient assessment. Noninvasive optical diagnostic techniques are increasingly used in clinical practice to increase diagnostic accuracy and characterize tumors in vivo before surgery or biopsy. The primary characteristics of cSCC, such as clustered vascular patterns, glomerular vessels, and hyperkeratosis, can be identified through dermoscopy. Reflectance confocal microscopy can reveal aberrant honeycomb or disorganized patterns in the epidermis' spinous-granular layer, round nucleated brilliant cells in the epidermis, and round dermis veins things. Moreover, dermoscopy is used more commonly in pigmented lesions than in non-pigmented lesions in the differential diagnosis of equivocal cases. Thus, from the above statements, the market is expected to drive market growth.

Restraint:

The high cost of the treatment, lack of reimbursement for the treatment, increase in complications rate, and lack of early detection of the diseases are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The cutaneous squamous cell carcinoma market provides in-depth analysis of the market based on various industry factors such as porter's five forces, supply chain analysis, reimbursement scenario, pipeline analysis, product innovation, pricing analysis, etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Medical and surgical operations for prevalent ailments have been delayed due to the lockdown. Moreover, Non-COVID patients had non-urgent medical visits canceled or postponed, and people were hesitant to contact healthcare services for fear of getting the virus and burdening the system further. This has resulted in a decrease in cancer diagnoses worldwide, particularly in skin malignancies. For instance, a Dutch study found a decline in weekly cancer diagnoses of up to 27% for all malignancies and 61% for skin cancers between the end of February and the beginning of April 2020.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Surgical segment is expected to hold the largest market share in cutaneous squamous cell carcinoma market

The surgical segment is expected to dominate in 2021. Most squamous cell carcinomas of the skin can be eliminated with minimal surgery or, on rare occasions, with a topical medication. The size, location, and aggressiveness of the tumor matter. For instance, Based on excellent cure rates and low recurrence rates reported in retrospective assessments of initial and recurrent cSCC, Mohs micrographic surgery (MMS) might be the best approach for high-risk patients. Moreover, if skin cancer is very small and has a low risk of spreading, less invasive treatments are the treatment choice. For instance, Curettage and electrodessication (C and E) treatment involves removing the skin cancer surface with a scraping instrument (curet) and then searing the base of the cancer with an electric needle. This treatment is often used for small or very superficial squamous cell skin cancers. Therefore, there is an increase in the demand for surgery. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global cutaneous squamous cell carcinoma market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of cutaneous squamous cell carcinoma, advancements in the treatment, well-established infrastructure and product launches and collaborations by the key players are some factors the market is expected to boost in the forecast period. For instance, Cutaneous squamous cell carcinoma (CSCC, also called squamous cell carcinoma of the skin) is the second most common form of skin cancer and five times more prevalent than melanoma in the U.S. Moreover, according to the American Cancer Society, Of nonmelanoma skin cancers, approximately 80% are basal cell carcinoma (BCC), and 20% are squamous cell carcinoma (SCC). In addition, Regeneron Pharmaceuticals, Inc. announced its intention to buy Sanofi's stake in the Regeneron and Sanofi collaboration on Libtayo (cemiplimab) on June 2, 2022 giving Regeneron exclusive global development, commercialization, and manufacturing rights to the medicine.

Furthermore, Merck & Co., Inc. received FDA approval for pembrolizumab (KEYTRUDA) in June 2020. The drug is approved to treat recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) resistant to surgery or radiation. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the cutaneous squamous cell carcinoma market are Regeneron Pharmaceuticals, Inc., Sanofi, Merck & Co., Inc., Mayne Pharma Group Limited, iNova Pharmaceuticals, Bristol-Myers Squibb Company, LGM PHARMA, Hikma Pharmaceuticals PLC, 3M Health Care Limited

Regeneron Pharmaceuticals, Inc.:

Overview:

Regeneron Pharmaceuticals, Inc. is a biotechnology business based in New York's Westchester County. The business was established in 1988. The company began by studying neurotrophic factors, and their regenerative abilities, hence its name, and subsequently expanded to include cytokine and tyrosine kinase receptor research. Currently, the company engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.

Product Portfolio:

LIBTAYO (cemiplimab-rwlc) injection: LIBTAYO is indicated for treating patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.

The global cutaneous squamous cell carcinoma market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.